Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus TACE in intermediate-stage HCC
NCT03572582Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Jun 2018
- Primary completion
- Oct 2021
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in hepatocellular carcinoma (HCC), sponsored by AIO-Studien. Primary endpoint: Objective Response Rate at 42 months. Started Jun 2018; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03572582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03572582.